CN103037888A - 增生性疾病的治疗 - Google Patents

增生性疾病的治疗 Download PDF

Info

Publication number
CN103037888A
CN103037888A CN2011800312370A CN201180031237A CN103037888A CN 103037888 A CN103037888 A CN 103037888A CN 2011800312370 A CN2011800312370 A CN 2011800312370A CN 201180031237 A CN201180031237 A CN 201180031237A CN 103037888 A CN103037888 A CN 103037888A
Authority
CN
China
Prior art keywords
seq
cancer
plant
nucleic acid
nad1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800312370A
Other languages
English (en)
Chinese (zh)
Inventor
马克·达雷恩·休利特
伊万·卡·霍·鹏
玛里琳·安妮·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIRSCHMAN CO Ltd
BALMORAL AUSTRALIA Pty Ltd
Original Assignee
HIRSCHMAN CO Ltd
BALMORAL AUSTRALIA Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIRSCHMAN CO Ltd, BALMORAL AUSTRALIA Pty Ltd filed Critical HIRSCHMAN CO Ltd
Publication of CN103037888A publication Critical patent/CN103037888A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
CN2011800312370A 2010-06-24 2011-06-23 增生性疾病的治疗 Pending CN103037888A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35812610P 2010-06-24 2010-06-24
US61/358,126 2010-06-24
PCT/AU2011/000760 WO2011160174A1 (en) 2010-06-24 2011-06-23 Treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
CN103037888A true CN103037888A (zh) 2013-04-10

Family

ID=45370753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800312370A Pending CN103037888A (zh) 2010-06-24 2011-06-23 增生性疾病的治疗

Country Status (12)

Country Link
US (1) US20120172313A1 (https=)
EP (1) EP2585095A4 (https=)
JP (1) JP2013530965A (https=)
KR (1) KR20140003316A (https=)
CN (1) CN103037888A (https=)
AU (1) AU2011269726B2 (https=)
CA (1) CA2803027A1 (https=)
MX (1) MX2012014711A (https=)
NZ (1) NZ603442A (https=)
SG (1) SG186385A1 (https=)
WO (1) WO2011160174A1 (https=)
ZA (1) ZA201208389B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111751345A (zh) * 2020-07-08 2020-10-09 深圳海关动植物检验检疫技术中心 一种苜蓿黄萎病菌活性检测方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825118C (en) 2011-02-07 2020-02-18 Hexima Limited Modified plant defensins useful as anti-pathogenic agents
WO2013039861A2 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2851144A1 (en) * 2011-10-19 2013-04-25 Hexima Limited Novel plant defensins and use in the treatment of proliferative diseases
SG11201708815UA (en) * 2015-05-29 2017-12-28 Hexima Ltd A method of in vivo treatment
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015024A1 (en) * 2008-08-05 2010-02-11 Hexima Limited Plant anti-pathogen systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124000T2 (de) * 2000-08-25 2007-06-28 Basf Plant Science Gmbh Neuartige, für na+/h+ antiporter kodierende pflanzliche polynukleotide
ATE510015T1 (de) * 2001-02-08 2011-06-15 Hexima Ltd Aus pflanzen stammende moleküle und diese codierende genetische sequenzen sowie verwendungen dafür
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015024A1 (en) * 2008-08-05 2010-02-11 Hexima Limited Plant anti-pathogen systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSE´ L. ANAYA-LO´PEZ ET AL.: "Fungicidal and cytotoxic activity of a Capsicum chinense defensin expressed by endothelial cells", 《BIOTECHNOL LETT》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111751345A (zh) * 2020-07-08 2020-10-09 深圳海关动植物检验检疫技术中心 一种苜蓿黄萎病菌活性检测方法

Also Published As

Publication number Publication date
SG186385A1 (en) 2013-01-30
JP2013530965A (ja) 2013-08-01
AU2011269726B2 (en) 2013-11-28
NZ603442A (en) 2013-09-27
MX2012014711A (es) 2013-03-21
KR20140003316A (ko) 2014-01-09
EP2585095A1 (en) 2013-05-01
AU2011269726A1 (en) 2012-11-29
ZA201208389B (en) 2013-06-26
CA2803027A1 (en) 2011-12-29
WO2011160174A1 (en) 2011-12-29
EP2585095A4 (en) 2013-11-13
US20120172313A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
Kim et al. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines
Lay et al. Defensins-components of the innate immune system in plants
Petersen et al. Peanut defensins: Novel allergens isolated from lipophilic peanut extract
Nair et al. Antimicrobial activity of omwaprin, a new member of the waprin family of snake venom proteins
CN103037888A (zh) 增生性疾病的治疗
Castro et al. Hylin a1, the first cytolytic peptide isolated from the arboreal South American frog Hypsiboas albopunctatus (“spotted treefrog”)
Mackintosh et al. A gloverin-like antibacterial protein is synthesized in Helicoverpa armigera following bacterial challenge
CN101801995A (zh) 抗菌肽
DE69936514T2 (de) Heliomycin-kodierendes gen und seine verwendung
US9540423B2 (en) Plant defensins and use in the treatment of proliferative diseases
Montesinos et al. Antimicrobial peptides for plant disease control. From discovery to application
Khan et al. Antimicrobial plant peptides: structure, classification, mechanism and therapeutic potential
Marcos et al. Antifungal peptides and proteins with activity against fungi causing postharvest decay
CN1634981B (zh) 一组新的抗菌肽及其制备方法和应用
Landi et al. Effects of indicitin, a novel ribosome-targeting enzyme from milky mushrooms, on four human cell lines and the gut microbiota
CN101781358B (zh) 一组新的抗菌肽及其制备方法和应用
Kaas et al. Antimicrobial peptides in plants.
AL SOUHAIL Characterization, regulation and biophysical studies of immune-related peptides from Manduca sexta
Ramadevi et al. Antimicrobial peptides and production of disease resistant transgenic plants
Barkhuizen Mode of action studies of defensin peptides from native South African Brassicaceae species
CN102391365B (zh) 一种抗菌肽及其制备方法和应用
Zhou Molecular cloning, structural characterisation and functional study of peptides from amphibian skin secretion
Srivastava Isolation and partial purification of antibacterial peptides from flowers of selected ornamental plants
Kumari Discovery and application of cysteine-rich peptides from medicinal plants in drug development
NZ622284B2 (en) Novel plant defensins and use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130410